Form 4: Trevi Therapeutics Director David P. Meeker Acquires 30,000 Stock Options

Director David P. Meeker acquired 30,000 nonstatutory stock options in Trevi Therapeutics, Inc. on June 13, 2024.

Summary

• On June 13, 2024, David P. Meeker, a director of Trevi Therapeutics, Inc., acquired 30,000 nonstatutory stock options.
• The exercise price of these options is $2.77.
• The options vest on the earlier of the first anniversary of the grant date or the date of the next annual meeting of stockholders following the grant date, contingent upon continued service.
• The options expire on June 12, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholder sentiment if viewed as a sign of confidence by a company insider.

Key Dates